Jessica Howard-Anderson1,2,3, Michelle Davis1,2, Alexander M Page1,2, Chris W Bower2,4,5, Gillian Smith2,4,5, Jesse T Jacob1,2,3, Dan I Andersson6, David S Weiss1,3,4, Sarah W Satola1,2,3,4. 1. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. 2. Georgia Emerging Infections Program, Decatur, GA, USA. 3. Emory Antibiotic Resistance Center, Atlanta, GA, USA. 4. Atlanta VA Medical Center, Decatur, GA, USA. 5. Foundation for Atlanta Veterans Education and Research, Decatur, GA, USA. 6. Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Abstract
OBJECTIVES: To describe the prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa (CRPA) and evaluate the association with clinical outcomes. METHODS: Colistin heteroresistance was evaluated in CRPA isolates collected from patients without cystic fibrosis in Atlanta, Georgia, USA using two definitions: HR1, growth at 4 and 8 mg/L of colistin at a frequency ≥1 × 10-6 the main population; and HR2, growth at a colistin concentration ≥8× the MIC of the main population at a frequency ≥1 × 10-7. A modified population analysis profile (mPAP) technique was compared with reference PAP for detecting heteroresistance. For adults hospitalized at the time of or within 1 week of CRPA culture, multivariable logistic regression estimated the association between heteroresistance and 90 day mortality. RESULTS: Of 143 colistin-susceptible CRPA isolates, 8 (6%) met the HR1 definition and 37 (26%) met the HR2 definition. Compared with the reference PAP, mPAP had a sensitivity and specificity of 50% and 100% for HR1 and 32% and 99% for HR2. Of 82 hospitalized patients, 45 (56%) were male and the median age was 63 years (IQR 49-73). Heteroresistance was not associated with 90 day mortality using HR1 (0% in heteroresistant versus 22% in non-heteroresistant group; P = 0.6) or HR2 (12% in heteroresistant versus 24% in non-heteroresistant group; P = 0.4; adjusted OR 0.8; 95% CI 0.2-3.4). CONCLUSIONS: Colistin heteroresistance was identified in up to 26% of patients with CRPA in our sample, although the prevalence varied depending on the definition. We did not observe an apparent association between colistin heteroresistance and 90 day mortality.
OBJECTIVES: To describe the prevalence of colistin heteroresistance in carbapenem-resistant Pseudomonas aeruginosa (CRPA) and evaluate the association with clinical outcomes. METHODS: Colistin heteroresistance was evaluated in CRPA isolates collected from patients without cystic fibrosis in Atlanta, Georgia, USA using two definitions: HR1, growth at 4 and 8 mg/L of colistin at a frequency ≥1 × 10-6 the main population; and HR2, growth at a colistin concentration ≥8× the MIC of the main population at a frequency ≥1 × 10-7. A modified population analysis profile (mPAP) technique was compared with reference PAP for detecting heteroresistance. For adults hospitalized at the time of or within 1 week of CRPA culture, multivariable logistic regression estimated the association between heteroresistance and 90 day mortality. RESULTS: Of 143 colistin-susceptible CRPA isolates, 8 (6%) met the HR1 definition and 37 (26%) met the HR2 definition. Compared with the reference PAP, mPAP had a sensitivity and specificity of 50% and 100% for HR1 and 32% and 99% for HR2. Of 82 hospitalized patients, 45 (56%) were male and the median age was 63 years (IQR 49-73). Heteroresistance was not associated with 90 day mortality using HR1 (0% in heteroresistant versus 22% in non-heteroresistant group; P = 0.6) or HR2 (12% in heteroresistant versus 24% in non-heteroresistant group; P = 0.4; adjusted OR 0.8; 95% CI 0.2-3.4). CONCLUSIONS: Colistin heteroresistance was identified in up to 26% of patients with CRPA in our sample, although the prevalence varied depending on the definition. We did not observe an apparent association between colistin heteroresistance and 90 day mortality.
Authors: Phillip J Bergen; Alan Forrest; Jürgen B Bulitta; Brian T Tsuji; Hanna E Sidjabat; David L Paterson; Jian Li; Roger L Nation Journal: Antimicrob Agents Chemother Date: 2011-08-29 Impact factor: 5.191
Authors: Victor I Band; Emily K Crispell; Brooke A Napier; Carmen M Herrera; Greg K Tharp; Kranthi Vavikolanu; Jan Pohl; Timothy D Read; Steven E Bosinger; M Stephen Trent; Eileen M Burd; David S Weiss Journal: Nat Microbiol Date: 2016-05-09 Impact factor: 17.745
Authors: Victor I Band; David A Hufnagel; Siddharth Jaggavarapu; Edgar X Sherman; Jessie E Wozniak; Sarah W Satola; Monica M Farley; Jesse T Jacob; Eileen M Burd; David S Weiss Journal: Nat Microbiol Date: 2019-06-17 Impact factor: 17.745
Authors: Bin Cai; Roger Echols; Glenn Magee; Juan Camilo Arjona Ferreira; Gareth Morgan; Mari Ariyasu; Takuko Sawada; Tsutae Den Nagata Journal: Open Forum Infect Dis Date: 2017-08-16 Impact factor: 3.835
Authors: Selena Chiu; Anna M Hancock; Bob W Schofner; Katherine J Sniezek; Nashaly Soto-Echevarria; Gabrielle Leon; Darshan M Sivaloganathan; Xuanqing Wan; Mark P Brynildsen Journal: J Antibiot (Tokyo) Date: 2022-09-20 Impact factor: 3.424